Literature DB >> 19729489

Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury.

Sony Prasad1, John Patrick McDaid, Frederick Wai Keung Tam, John Lionel Haylor, Albert Chee Meng Ong.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) results from mutations in either PKD1 or PKD2 and accounts for 10% of all patients on renal replacement therapy. The kidney disease phenotype is primarily characterized by cyst formation, but there are also prominent interstitial changes (inflammation, apoptosis, proliferation, and fibrosis). Using a model of unilateral ischemia-reperfusion injury, we tested the hypothesis that Pkd2 heterozygous kidneys are more sensitive to injury and that this could lead to interstitial inflammation and fibrosis. Baseline tubular proliferation in heterozygous kidneys was twofold higher than in wild-type kidneys. The magnitude and duration of tubular and interstitial proliferative responses was consistently greater in injured heterozygous compared with wild-type kidneys at all time points. Conversely, tubular p21 expression in heterozygotes was lower at baseline and following injury at all time points. Significantly more neutrophils and macrophages were detected in injured Pkd2 heterozygous kidneys at 2 days, correlating with increased expression of the cytokines interleukin (IL)-1beta and keratinocyte-derived chemokine and resulting in interstitial fibrosis at 28 days. We conclude that Pkd2 dosage influences both susceptibility and nature of the repair responses following injury. Polycystin-2 is therefore likely to play multiple roles in regulating tubular cell viability, repair, and remodeling in the mature kidney.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729489      PMCID: PMC2751546          DOI: 10.2353/ajpath.2009.090227

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  Polycystic kidney disease.

Authors:  Patricia D Wilson
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

2.  Cardiac defects and renal failure in mice with targeted mutations in Pkd2.

Authors:  G Wu; G S Markowitz; L Li; V D D'Agati; S M Factor; L Geng; S Tibara; J Tuchman; Y Cai; J H Park; J van Adelsberg; H Hou; R Kucherlapati; W Edelmann; S Somlo
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

3.  PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2.

Authors:  Anil Kumar Bhunia; Klaus Piontek; Alessandra Boletta; Lijuan Liu; Feng Qian; Pei Ning Xu; F Joseph Germino; Gregory G Germino
Journal:  Cell       Date:  2002-04-19       Impact factor: 41.582

4.  Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure.

Authors:  J Megyesi; L Andrade; J M Vieira; R L Safirstein; P M Price
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

5.  Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease.

Authors:  Riccardo Magistroni; Ning He; Kairong Wang; Robin Andrew; Ann Johnson; Patricia Gabow; Elizabeth Dicks; Patrick Parfrey; Roser Torra; Jose L San-Millan; Eliecer Coto; Marjan Van Dijk; Martijn Breuning; Dorien Peters; Nadja Bogdanova; Giulia Ligabue; Alberto Albertazzi; Nick Hateboer; Kyproula Demetriou; Alkis Pierides; Constantinos Deltas; Peter St George-Hyslop; David Ravine; York Pei
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

6.  Polycystin-2 expression is increased following experimental ischaemic renal injury.

Authors:  Yan Zhao; John L Haylor; Albert C M Ong
Journal:  Nephrol Dial Transplant       Date:  2002-12       Impact factor: 5.992

7.  The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.

Authors:  Sandro Rossetti; Sarah Burton; Lana Strmecki; Gregory R Pond; Jośe L San Millán; Klaus Zerres; T Martin Barratt; Seza Ozen; Vicente E Torres; Erik J Bergstralh; Christopher G Winearls; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2002-05       Impact factor: 10.121

8.  Molecular cytogenetic aberrations in autosomal dominant polycystic kidney disease tissue.

Authors:  Jean Gogusev; Ichiro Murakami; Mireille Doussau; Louise Telvi; Alexandre Stojkoski; Philippe Lesavre; Dominique Droz
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

9.  Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.

Authors:  Hester Happé; Wouter N Leonhard; Annemieke van der Wal; Bob van de Water; Irma S Lantinga-van Leeuwen; Martijn H Breuning; Emile de Heer; Dorien J M Peters
Journal:  Hum Mol Genet       Date:  2009-04-28       Impact factor: 6.150

10.  Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells.

Authors:  Qi Qian; Larry W Hunter; Ming Li; Miguel Marin-Padilla; Y S Prakash; Stefan Somlo; Peter C Harris; Vicente E Torres; Gary C Sieck
Journal:  Hum Mol Genet       Date:  2003-08-01       Impact factor: 6.150

View more
  32 in total

1.  Phosphoinositide 3-Kinase-C2α Regulates Polycystin-2 Ciliary Entry and Protects against Kidney Cyst Formation.

Authors:  Irene Franco; Jean Piero Margaria; Maria Chiara De Santis; Andrea Ranghino; Daniel Monteyne; Marco Chiaravalli; Monika Pema; Carlo Cosimo Campa; Edoardo Ratto; Federico Gulluni; David Perez-Morga; Stefan Somlo; Giorgio R Merlo; Alessandra Boletta; Emilio Hirsch
Journal:  J Am Soc Nephrol       Date:  2015-08-13       Impact factor: 10.121

Review 2.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 3.  Autophagy and regulation of cilia function and assembly.

Authors:  I Orhon; N Dupont; O Pampliega; A M Cuervo; P Codogno
Journal:  Cell Death Differ       Date:  2014-10-31       Impact factor: 15.828

Review 4.  Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Authors:  Wouter N Leonhard; Hester Happe; Dorien J M Peters
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

Review 5.  Kidney: polycystic kidney disease.

Authors:  Binu M Paul; Gregory B Vanden Heuvel
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2014-09-03       Impact factor: 5.814

6.  Environmental hit on a genetic basis in polycystic kidney disease.

Authors:  Shixuan Wang; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

7.  G-protein signaling modulator 1 deficiency accelerates cystic disease in an orthologous mouse model of autosomal dominant polycystic kidney disease.

Authors:  Michelle Kwon; Tengis S Pavlov; Kandai Nozu; Shauna A Rasmussen; Daria V Ilatovskaya; Alexandra Lerch-Gaggl; Lauren M North; Hyunho Kim; Feng Qian; William E Sweeney; Ellis D Avner; Joe B Blumer; Alexander Staruschenko; Frank Park
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

8.  Protein kinase D-mediated phosphorylation of polycystin-2 (TRPP2) is essential for its effects on cell growth and calcium channel activity.

Authors:  Andrew J Streets; Andrew J Needham; Sharonjit K Gill; Albert C M Ong
Journal:  Mol Biol Cell       Date:  2010-09-29       Impact factor: 4.138

9.  Cyst formation in the PKD2 (1-703) transgenic rat precedes deregulation of proliferation-related pathways.

Authors:  Panayiota Koupepidou; Kyriacos N Felekkis; Bettina Kränzlin; Carsten Sticht; Norbert Gretz; Constantinos Deltas
Journal:  BMC Nephrol       Date:  2010-09-02       Impact factor: 2.388

10.  The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.

Authors:  Jeffrey J Talbot; Xuewen Song; Xiaofang Wang; Markus M Rinschen; Nicholas Doerr; Wells B LaRiviere; Bernhard Schermer; York P Pei; Vicente E Torres; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.